IR News 2017

Outline of Consolidated Financial Results for the Second Quarter Ended September 30, 2017

Revision of Performance Projection, Dividend of Surplus (Interim Dividend) and Revision of Year-end Dividend Forecast

Revision of Performance Projection

New Drug Application Filed for Glycoengineered Type II Anti-CD20 Monoclonal Antibody, Obinutuzumab

Outline of Consolidated Financial Results for the First Quarter Ended June 30, 2017

Nippon Shinyaku Co., Ltd. announces final completion of a manufacturing plant for highly active solid formulations

Outline of Consolidated Financial Results for the Year Ended March 31, 2017

Revision of Performance Projection and Dividend Forecast

Nippon Shinyaku enters into license agreements with Jazz Pharmaceuticals plc for Defitelio® and Vyxeos™

Nippon Shinyaku enters into a license agreement with Delta-Fly Pharma on DFP-10917, a therapeutic agent for relapsed/refractory acute myeloid leukemia

Outline of Consolidated Financial Results for the Third Quarter Ended December 31, 2016

FDA Grants Rare Pediatric Disease Designation to NS-065/NCNP-01 for the Treatment of Duchenne Muscular Dystrophy

First Patient Dosed in Phase 2 Clinical Study of NS-065/NCNP-01 for the Treatment of Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping

FDA Grants Orphan Drug Designation to NS-065/NCNP-01 for the Treatment of Duchenne Muscular Dystrophy